^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD37 expression

    i
    Other names: CD37, CD37 Molecule, TSPAN26, Leukocyte Antigen CD37, Tetraspanin-26, CD37 Antigen, Tspan-26, Cell Differentiation Antigen 37, Leukocyte Surface Antigen CD37, GP52-40
    Entrez ID:
    951
    3ms
    PI3Kδ activation, IL6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas. (PubMed, Blood Adv)
    Anti-IL6 antibody tocilizumab improved the ADC's cytotoxic activity in CD37+ cells...Adding idelalisib or venetoclax overcame resistance in the resistant derivative and improved the cytotoxic activity in the parental cells. In conclusion, targeting B-cell lymphoma with the naratuximab emtansine showed vigorous anti-tumor activity as a single agent, which was also observed in models bearing genetic lesions associated with inferior outcomes, such as MYC translocations and TP53 inactivation or R-CHOP resistance. Resistant DLBCL models identified active combinations of naratuximab emtansine with drugs targeting IL6, PI3Kδ, and BCL2.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • IL6 (Interleukin 6) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • CD37 (CD37 Molecule)
    |
    MYC translocation • CD37 expression • PIK3CD mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Zydelig (idelalisib) • Actemra IV (tocilizumab) • naratuximab emtansine (DEBIO 1562)
    3ms
    CD37 in acute myeloid leukemia: a novel surface target for drug delivery. (PubMed, Blood Adv)
    Our work revealed that the clinically relevant anti-CD37 antibody drug conjugate (ADC) Debio 1562 (αCD37-DM1) is highly cytotoxic to AML blasts, but not normal hematopoietic stem cells. We found that αCD37-DM1 improved clinical outcomes and overall survival in multiple in vivo models of AML. Together, these data demonstrate that targeting CD37 with an ADC such as αCD37-DM1 is a feasible and promising therapeutic option for the treatment of AML.
    Journal
    |
    CD37 (CD37 Molecule)
    |
    CD37 expression
    |
    naratuximab emtansine (DEBIO 1562)
    3ms
    Prognostic value and imaging features of (18)F-FDG PET-CT in follicular lymphoma with different histopathology grade (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    β(2)-MG (>2.3 μg/L) , Follicular lymphoma international prognostic index-1 (FLIPI-1) score (3-5 points) , negative CD37 expression, positive c-Myc expression, and TLG (>2 342.55 g) were all independent risk factors for PFS in the FL patients (HR=3.609, 2.509, 0.255, 3.506, 13.531, all P value<0.05) . (18)F-FDG PET-CT is a powerful complement to FL histopathological grading and the combination of the two may better predict the prognosis of FL patients.
    Retrospective data • Journal • FDG PET
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • MME (Membrane Metalloendopeptidase) • CD37 (CD37 Molecule)
    |
    MYC expression • MYC positive • CD37 expression
    9ms
    Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation. (PubMed, Stem Cell Res Ther)
    ALA and ELK1 are found to regulate both human granulopoiesis and erythropoiesis via RNA spliceosome, and ALA-ELK1 signal might be the target of human leukemia therapy.
    Journal • IO biomarker
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CD37 (CD37 Molecule) • ELK1 (ETS Transcription Factor ELK1)
    |
    CD38 expression • TFRC expression • CD37 expression
    10ms
    CAR-37 T Cells In Hematologic Malignancies (clinicaltrials.gov)
    P1, N=6, Completed, Marcela V. Maus, M.D.,Ph.D. | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
    Trial completion • Trial completion date
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • CD37 (CD37 Molecule)
    |
    TP53 mutation • CD37 expression
    1year
    CAR-37 T Cells In Hematologic Malignancies (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Marcela V. Maus, M.D.,Ph.D. | Recruiting --> Active, not recruiting | N=18 --> 6
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • CD37 (CD37 Molecule)
    |
    TP53 mutation • CD37 expression
    1year
    Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia. (PubMed, J Int Med Res)
    Patients with CD371-positive B-ALL exhibit a specific signature that merits further analysis, particularly because it has been associated with DUX4 rearrangement.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MME (Membrane Metalloendopeptidase) • CD37 (CD37 Molecule) • DUX4 (Double Homeobox 4)
    |
    PTPRC expression • TFRC expression • CD37 expression
    over1year
    A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=6, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial • CAR T-Cell Therapy
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • IL18 (Interleukin 18) • CD37 (CD37 Molecule)
    |
    FLT3-ITD mutation • IDH1 mutation • IDH2 mutation • CD37 expression
    |
    CD371-YSNVZ-IL18 CAR T cells